X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Notable and MDS Foundation Partner on MDS Trials and New Drug Therapies

Content Team by Content Team
4th May 2020
in News
J&J collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate manufacturing

California-based Notable announced on Thursday that it has entered a partnership with the MDS Foundation, which is dedicated to providing insight to families on future clinical trials for myelodysplastic syndrome (MDS).

Notable will offer a grant to support the MDS Foundation’s education and advocacy efforts, and both companies will work closely to engage physicians, biopharmaceutical companies, health authorities and clinical trial organizations to collaborate on clinical trial designs. Ideally, both groups want to match patients to more effective drug therapies and get therapies approved faster for the benefit of all patients.

“Notable has breakthrough technology for accelerating drug development and precision medicine, matching patients with effective therapies,” said Tracey Iraca, Executive Director of the MDS Foundation. “We are excited to work closely with Notable to continue to learn more about what its platform will mean for MDS research and help translate important information about MDS developments and trials to our community.”

The MDS Foundation intends to connect the Notable team with MDS research through its Centers of Excellence network. Notable’s staff will have access to information on available clinical trials, as well as new research and treatment options.

“The MDS Foundation is paramount for communicating and educating the MDS community about groundbreaking research and treatments in this field,” said Laurie Heilmann, CEO of Notable. “The combination of our scientific technology platform and the MDS Foundation’s charter will help advance functional precision medicine while educating patients and families about the latest clinical trials available.”

Notable is known for its clinically validated artificial intelligence (AI) platform, which advances cancer drug development at a fraction of traditional costs. Its approach combines AI with an automated lab to determine which drugs will be most effective for treating specific types of cancer. In a clinical trial, Notable achieved an 84% overall accuracy rate in predicting patient response to prescribed drugs.

Notable was started by Matt De Silva, who initially began the company to help his father, who was living with brain cancer.

“Patients with aggressive cancers are in a race against time, but if we can use technology to identify the best drug or drug combination at the time of diagnosis, there is a much better chance those therapies will work,” said De Silva back in 2019. “We are eager to scale the results we’ve generated with our academic collaborators by expanding our AI platform and automated laboratory to more cancer types.

Notable announced a $40 million Series B round of funding in July of last year. The round was led by B Capital Group and LifeForce Capital, and it brought the company’s total funding to over $55 million.

“We’ve seen what Notable’s technology platform can do to predict patient responses to cancer drugs,” said Adam Seabrook of B Capital Group. “They affect patients today by finding the best therapy for each specific patient in a way that other precision medicine tools can’t. That same platform is also ideally suited to identify new therapies and accelerate their progress through clinical trials. We are thrilled to invest our time and resources to help Notable deliver precision medicine to patients today and accelerate research on the next generation of therapies in the fight against cancer.”

Notable’s approach has been validated by several independent clinical studies conducted by establishments including Stanford University, University of California San Francisco, Rady Children’s Hospital and Texas Children’s Hospital.

Previous Post

Quotient Limited Announces CE Mark for its SARS-CoV-2 Antibody Microarray

Next Post

DNA Genotek's ORAcollect RNA kit included in EUA granted to Biocerna SARS-CoV-2 test

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

DNA Genotek's ORAcollect RNA kit included in EUA granted to Biocerna SARS-CoV-2 test

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In